Abacavir/Dolutegravir/Lamivudine (Triumeq)–Induced Liver Toxicity in a Human Immunodeficiency Virus–Infected Patient

Drug-induced liver injury related to Triumeq (abacavir/lamivudine/dolutegravir) has not been reported in clinical trials. We report a case of hepatotoxicity related to Triumeq exposure in a human immunodeficiency virus–infected patient. Clinicians should remain aware of the risk for acute and late-o...

Descripción completa

Detalles Bibliográficos
Autores principales: Christensen, Erin S., Jain, Rupali, Roxby, Alison C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522577/
https://www.ncbi.nlm.nih.gov/pubmed/28748198
http://dx.doi.org/10.1093/ofid/ofx122
_version_ 1783252200163639296
author Christensen, Erin S.
Jain, Rupali
Roxby, Alison C.
author_facet Christensen, Erin S.
Jain, Rupali
Roxby, Alison C.
author_sort Christensen, Erin S.
collection PubMed
description Drug-induced liver injury related to Triumeq (abacavir/lamivudine/dolutegravir) has not been reported in clinical trials. We report a case of hepatotoxicity related to Triumeq exposure in a human immunodeficiency virus–infected patient. Clinicians should remain aware of the risk for acute and late-onset hepatitis with these agents. Close monitoring is recommended.
format Online
Article
Text
id pubmed-5522577
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-55225772017-07-26 Abacavir/Dolutegravir/Lamivudine (Triumeq)–Induced Liver Toxicity in a Human Immunodeficiency Virus–Infected Patient Christensen, Erin S. Jain, Rupali Roxby, Alison C. Open Forum Infect Dis Brief Report Drug-induced liver injury related to Triumeq (abacavir/lamivudine/dolutegravir) has not been reported in clinical trials. We report a case of hepatotoxicity related to Triumeq exposure in a human immunodeficiency virus–infected patient. Clinicians should remain aware of the risk for acute and late-onset hepatitis with these agents. Close monitoring is recommended. Oxford University Press 2017-06-12 /pmc/articles/PMC5522577/ /pubmed/28748198 http://dx.doi.org/10.1093/ofid/ofx122 Text en © The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Brief Report
Christensen, Erin S.
Jain, Rupali
Roxby, Alison C.
Abacavir/Dolutegravir/Lamivudine (Triumeq)–Induced Liver Toxicity in a Human Immunodeficiency Virus–Infected Patient
title Abacavir/Dolutegravir/Lamivudine (Triumeq)–Induced Liver Toxicity in a Human Immunodeficiency Virus–Infected Patient
title_full Abacavir/Dolutegravir/Lamivudine (Triumeq)–Induced Liver Toxicity in a Human Immunodeficiency Virus–Infected Patient
title_fullStr Abacavir/Dolutegravir/Lamivudine (Triumeq)–Induced Liver Toxicity in a Human Immunodeficiency Virus–Infected Patient
title_full_unstemmed Abacavir/Dolutegravir/Lamivudine (Triumeq)–Induced Liver Toxicity in a Human Immunodeficiency Virus–Infected Patient
title_short Abacavir/Dolutegravir/Lamivudine (Triumeq)–Induced Liver Toxicity in a Human Immunodeficiency Virus–Infected Patient
title_sort abacavir/dolutegravir/lamivudine (triumeq)–induced liver toxicity in a human immunodeficiency virus–infected patient
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522577/
https://www.ncbi.nlm.nih.gov/pubmed/28748198
http://dx.doi.org/10.1093/ofid/ofx122
work_keys_str_mv AT christensenerins abacavirdolutegravirlamivudinetriumeqinducedlivertoxicityinahumanimmunodeficiencyvirusinfectedpatient
AT jainrupali abacavirdolutegravirlamivudinetriumeqinducedlivertoxicityinahumanimmunodeficiencyvirusinfectedpatient
AT roxbyalisonc abacavirdolutegravirlamivudinetriumeqinducedlivertoxicityinahumanimmunodeficiencyvirusinfectedpatient

Ejemplares similares